Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 4/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6053123 | 0.84 | KMT2A (0.37) | KMT2AMEN1ALDH1A1TSHRTDP1 | |
| SCHEMBL6053122 | 0.83 | MEN1 (0.38) | KMT2AMEN1ALDH1A1TSHRTDP1 | |
| SCHEMBL7820712 | 0.80 | TDP1 (0.42) | KMT2AMEN1ALDH1A1TSHRTDP1 | |
| SCHEMBL9197708 | 0.79 | TDP1 (0.41) | KMT2AMEN1ALDH1A1TSHRTDP1 | |
| SCHEMBL8016459 | 0.78 | KMT2A (0.39) | KMT2AMEN1ALDH1A1TSHRTDP1 | |
| SCHEMBL3439144 | 0.74 | MEN1 (0.35) | KMT2AMEN1ALDH1A1TSHRTDP1 | |
| SCHEMBL4714065 | 0.74 | TDP1 (0.52) | KMT2AMEN1ALDH1A1TSHRTDP1 | |
| SCHEMBL13546218 | 0.73 | TDP1 (0.39) | KMT2AMEN1ALDH1A1TSHRTDP1 | |
| SCHEMBL1696854 | 0.72 | TDP1 (0.47) | KMT2AMEN1ALDH1A1TSHRTDP1 | |
| SCHEMBL9154472 | 0.72 | KMT2A (0.41) | KMT2AMEN1ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3914435-B2 | — | — | 2007-05-16 | — | — | JP | claimed |
| US-20050137414-A1 | New aminopropylphosphinic acids | ELEBRING THOMAS (SE) | 2005-06-23 | — | — | US | claimed |
| JP-2003516407-A | — | — | 2003-05-13 | — | — | JP | claimed |
| US-20020156053-A1 | New aminopropylphosphinic acids | GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT | 2002-10-24 | — | — | US | claimed |
| EP-1240172-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | claimed |
| WO-2001042252-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | claimed |
| US-7807658-B2 | Use of GabaB receptor agonists | ASTRAZENECA AB (SE) | 2010-10-05 | — | — | US | disclosed |
| US-20080146836-A1 | New Aminopropylphosphinic acids | ELEBRING THOMAS | 2008-06-19 | — | — | US | disclosed |
| US-20070021393-A1 | New use of GabaB receptor agonists | LEHMANN ANDERS | 2007-01-25 | — | — | US | disclosed |
| US-7034176-B2 | Aminopropylphosphinic acids | ASTRAZENECA AB (SE) | 2006-04-25 | — | — | US | disclosed |
| US-20050137414-A1 | New aminopropylphosphinic acids | ELEBRING THOMAS (SE) | 2005-06-23 | — | — | US | disclosed |
| US-6841698-B2 | GABAB Receptor Agonists; used to treat gastrointestinal disorders, especially GERD | ASTRAZENECA AB (SE) | 2005-01-11 | — | — | US | disclosed |
| EP-1484333-A1 | New aminopropylphosphonous acids | AstraZeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| EP-1240172-B1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2004-11-10 | — | — | EP | disclosed |
| US-20030220303-A1 | New aminopropylphosphinic acids | ELEBRING THOMAS (SE) | 2003-11-27 | — | — | US | disclosed |
| US-6576626-B2 | Treating gastro-oesophageal reflux disease | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | disclosed |
| US-20020156053-A1 | New aminopropylphosphinic acids | GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220303-A1 | New aminopropylphosphinic acids | GABRP, GABRB1, GABRA1 | KMT2A 3339/4885MEN1 3676/4885ALDH1A1 1394/4885 |
| US-20080146836-A1 | New Aminopropylphosphinic acids | GABRP, GABRA1, GABRA5 | KMT2A 3083/4885MEN1 3186/4885ALDH1A1 1489/4885 |
| US-20020156053-A1 | New aminopropylphosphinic acids | GABRP, GABRB1, GABRA1 | KMT2A 3339/4885MEN1 3676/4885ALDH1A1 1394/4885 |
| US-20070021393-A1 | New use of GabaB receptor agonists | GABRA1, GABRA3, GABRB1 | KMT2A 3037/4885MEN1 3539/4885ALDH1A1 1186/4885 |
| US-20050137414-A1 | New aminopropylphosphinic acids | GABRP, GABRA1, GABRA5 | KMT2A 3083/4885MEN1 3186/4885ALDH1A1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.